PriorityMedicare step therapy requirementsPriorityMedicareSM plans at times require use of first-line agents or classes of products before certain drugs or classes of drugs may be approved. The process is commonly referred to as step therapy.Considerations in this process may include clinical effectiveness, potential for adverse events, and total overall cost of therapy. This is especially important since many new drugs do not offer significant clinical advantages, but come with a much higher cost. Documenting Therapeutic Trial and Clinical Failure The Pharmacy and Therapeutics Committee has approved the requirement for a physician to show documented evidence of therapeutic trial and clinical failure of a drug or drug class before PriorityMedicare plans will authorize the use of specific agents. Exceptions may be granted on a case-by-case basis taking individual information into consideration. Classes with Step Therapy Requirements Click on any class to jump to the protocol for that class. Allergic Rhinitis Therapy Anti-Depressant Therapy Angiotensin Receptor Blocker (ARB) Therapy Non-Sedating Antihistamine (NSA) Therapy NSA-Decongestant Therapy Asthma Therapy Proton Pump Inhibitor (PPI) Therapy Allergic Rhinitis Step Therapy Criteria for use of Singulair: The purpose of this step therapy protocol is to confirm that a patient using Singulair is using it for the treatment of an asthmatic condition rather than as a first line agent for allergic rhinitis. If a patient has a history of using any of the following drugs a claim for Singulair will process. If there is no history of using any of the following drugs, the claim will not process.
Anti-Depressant Therapy New prescriptions only
There are multiple purposes for this step therapy protocol for new prescriptions only. Meeting the step therapy requirements for a new prescription will automatically allow a member to receive future prescriptions.
Angiotensin Receptor Blocker (ARB) Therapy
Non-Sedating Antihistamine (NSA) Therapy
Non-Sedating Antihistimine (NSA) Decongestant Therapy
Asthma Therapy
Proton Pump Inhibitor (PPI) Therapy
H2320_4000_4006_62 F&U (12/07) S5857_4000_4006_62 F&U (12/07)
Last modified
12/19/07
|
